Cynata Therapeutics Limited (CYP.AX)
AUD 0.2
(0.0%)
AUD 0.2
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -9.74 Million AUD | 31.75% |
| 2023 | -14.27 Million AUD | -162.2% |
| 2022 | -5.44 Million AUD | 29.19% |
| 2021 | -7.68 Million AUD | -111.31% |
| 2020 | -3.63 Million AUD | 57.05% |
| 2019 | -8.47 Million AUD | -85.54% |
| 2018 | -4.56 Million AUD | -0.28% |
| 2017 | -4.55 Million AUD | 7.81% |
| 2016 | -4.93 Million AUD | -33.06% |
| 2015 | -3.71 Million AUD | -22.12% |
| 2014 | -3.03 Million AUD | -231.95% |
| 2013 | -915.7 Thousand AUD | 40.63% |
| 2012 | -1.54 Million AUD | 39.87% |
| 2011 | -2.56 Million AUD | -21.21% |
| 2010 | -2.11 Million AUD | -92.15% |
| 2009 | -1.1 Million AUD | 25.93% |
| 2008 | -1.48 Million AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.54 Million AUD | 0.0% |
| 2024 FY | -9.74 Million AUD | 31.75% |
| 2024 Q4 | -5.2 Million AUD | 0.0% |
| 2023 Q2 | -5.17 Million AUD | 0.0% |
| 2023 Q4 | -9.1 Million AUD | 0.0% |
| 2023 FY | -14.27 Million AUD | -162.2% |
| 2022 Q2 | -1.13 Million AUD | 0.0% |
| 2022 Q4 | -4.31 Million AUD | 0.0% |
| 2022 FY | -5.44 Million AUD | 29.19% |
| 2021 Q2 | -4.83 Million AUD | 0.0% |
| 2021 FY | -7.68 Million AUD | -111.31% |
| 2021 Q4 | -2.85 Million AUD | 0.0% |
| 2020 Q2 | -2.54 Million AUD | 0.0% |
| 2020 FY | -3.63 Million AUD | 57.05% |
| 2020 Q4 | -1.09 Million AUD | 0.0% |
| 2019 Q2 | -2.98 Million AUD | 0.0% |
| 2019 FY | -8.47 Million AUD | -85.54% |
| 2019 Q4 | -5.49 Million AUD | 0.0% |
| 2018 Q4 | -2.75 Million AUD | 0.0% |
| 2018 FY | -4.56 Million AUD | -0.28% |
| 2018 Q2 | -1.81 Million AUD | 0.0% |
| 2017 Q4 | -3.53 Million AUD | 0.0% |
| 2017 Q2 | -1.02 Million AUD | 0.0% |
| 2017 FY | -4.55 Million AUD | 7.81% |
| 2016 Q2 | -2.46 Million AUD | 0.0% |
| 2016 Q4 | -2.47 Million AUD | 0.0% |
| 2016 FY | -4.93 Million AUD | -33.06% |
| 2015 FY | -3.71 Million AUD | -22.12% |
| 2015 Q4 | -2.29 Million AUD | 0.0% |
| 2015 Q2 | -1.41 Million AUD | 0.0% |
| 2014 FY | -3.03 Million AUD | -231.95% |
| 2014 Q4 | -1.31 Million AUD | 0.0% |
| 2014 Q2 | -1.72 Million AUD | 0.0% |
| 2013 Q3 | -228.92 Thousand AUD | 39.85% |
| 2013 Q2 | -380.6 Thousand AUD | 1.29% |
| 2013 Q1 | -385.57 Thousand AUD | 0.0% |
| 2013 FY | -915.7 Thousand AUD | 40.63% |
| 2013 Q4 | -535.1 Thousand AUD | -133.74% |
| 2012 Q4 | - AUD | 100.0% |
| 2012 Q2 | -385.57 Thousand AUD | 39.87% |
| 2012 Q1 | -641.24 Thousand AUD | 0.0% |
| 2012 FY | -1.54 Million AUD | 39.87% |
| 2012 Q3 | -385.57 Thousand AUD | 0.0% |
| 2011 Q4 | - AUD | 100.0% |
| 2011 Q3 | -641.24 Thousand AUD | 0.0% |
| 2011 Q2 | -641.24 Thousand AUD | -21.21% |
| 2011 Q1 | -529.03 Thousand AUD | 0.0% |
| 2011 FY | -2.56 Million AUD | -21.21% |
| 2010 Q3 | -529.03 Thousand AUD | 0.0% |
| 2010 Q2 | -529.03 Thousand AUD | -45.91% |
| 2010 Q4 | - AUD | 100.0% |
| 2010 Q1 | -362.56 Thousand AUD | 0.0% |
| 2010 FY | -2.11 Million AUD | -92.15% |
| 2009 Q2 | -362.56 Thousand AUD | 28.73% |
| 2009 FY | -1.1 Million AUD | 25.93% |
| 2009 Q3 | -362.56 Thousand AUD | 0.0% |
| 2009 Q1 | -508.71 Thousand AUD | 0.0% |
| 2009 Q4 | - AUD | 100.0% |
| 2008 Q4 | - AUD | 100.0% |
| 2008 Q2 | -508.71 Thousand AUD | 0.0% |
| 2008 FY | -1.48 Million AUD | 0.0% |
| 2008 Q3 | -508.71 Thousand AUD | 0.0% |
| 2008 Q1 | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2007 Q2 | - AUD | 0.0% |
| 2007 Q3 | - AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | -81.086% |
| Acrux Limited | -5.8 Million AUD | -68.012% |
| Actinogen Medical Limited | -13.04 Million AUD | 25.295% |
| AnteoTech Limited | -8.88 Million AUD | -9.731% |
| Argenica Therapeutics Limited | -5.47 Million AUD | -77.84% |
| Arovella Therapeutics Limited | -8.74 Million AUD | -11.419% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -571.474% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 49.043% |
| Amplia Therapeutics Limited | -4.5 Million AUD | -116.383% |
| Avecho Biotechnology Limited | -3.43 Million AUD | -183.56% |
| Bio-Gene Technology Limited | -2.4 Million AUD | -304.483% |
| Biome Australia Limited | -1.67 Million AUD | -483.445% |
| Biotron Limited | -3.43 Million AUD | -183.563% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 29.741% |
| BTC Health Limited | 1.05 Million AUD | 1023.418% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 22.228% |
| CSL Limited | 2.64 Billion AUD | 100.369% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 76.976% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 127.345% |
| Dimerix Limited | -17.07 Million AUD | 42.93% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 239.92% |
| Hexima Limited | -933.87 Thousand AUD | -943.473% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | -240.21% |
| Immuron Limited | -6.93 Million AUD | -40.475% |
| Immutep Limited | -39.89 Million AUD | 75.575% |
| Imugene Limited | -149.68 Million AUD | 93.49% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -493.535% |
| Memphasys Limited | -4.44 Million AUD | -119.376% |
| Nanollose Limited | -1.15 Million AUD | -742.565% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 106.204% |
| Noxopharm Limited | -3.57 Million AUD | -172.342% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 3105.678% |
| Nyrada Inc. | -1.38 Million AUD | -602.966% |
| Orthocell Limited | -7.18 Million AUD | -35.702% |
| PharmAust Limited | -9.03 Million AUD | -7.887% |
| Patrys Limited | -3.53 Million AUD | -175.34% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 83.386% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | -52.829% |
| Prescient Therapeutics Limited | -8.23 Million AUD | -18.289% |
| PYC Therapeutics Limited | -37.72 Million AUD | 74.169% |
| Race Oncology Limited | -13.81 Million AUD | 29.485% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 79.677% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 44.826% |
| Starpharma Holdings Limited | -8.16 Million AUD | -19.347% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 287.003% |
| Tissue Repair Ltd | -4.13 Million AUD | -135.487% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 73.352% |